HAB Pharmaceuticals has set ambitious revenue targets of ₹2,500 crore to ₹3,000 crore by 2030 following its merger with Signature Phytochemical Industries through a slump sale deal finalised in March 2026. According to company statements, the operational consolidation was undertaken to streamline manufacturing systems, integrate corporate governance frameworks, and establish a platform for long-term growth. The transaction brings both companies under a single consolidated entity with an initial combined turnover of approximately ₹600 crore, net of inter-company sales. The merger was finalized in March this year and plans to achieve ₹3,000 crore in revenue by 2030 through a focus on off-patent molecules in oncology, autoimmune disorders, chronic conditions, and rare diseases.
To support its 2030 growth targets, HAB Pharma is preparing to commission two new manufacturing facilities, with commercial production scheduled to begin by August 2026. The first facility is a sterile manufacturing unit configured for injectables, vials, prefilled syringes, lyophilised products, and semaglutide production. The second facility is an automated, closed-loop oral solid dosage plant designed to increase bulk tablet and capsule output. Established in 1991, HAB Pharma currently operates manufacturing units in Mumbai and Dehradun, producing standard therapeutic formulations including antibiotics, non-steroidal anti-inflammatory drugs, and cardiovascular medications. The Mumbai-based drug maker has also announced to commission two new manufacturing plants — a sterile facility for prefilled syringes including weight-loss drug semaglutide and and a fully automated closed-loop oral solid dosage (OSD) plant.
The merger with Signature Phytochemical Industries, established in 2016, expands the group's capacity in manufacturing tablets, capsules, and creams. The consolidated entity plans to utilise its combined research and development infrastructure to enter specialised product segments, including oncology, autoimmune disorders, chronic conditions, and rare diseases. The company currently exports to over 17 countries and has completed regulatory audits in nations including Uganda, Tanzania, and Iraq. The post-merger commercial strategy focuses on expanding distribution networks across Latin America, Central Asia, and South-East Asia. The merged entity is looking to target various markets across Latin America, Central Asia, and Southeast Asia.
According to company directors, the merger positions HAB Pharma for substantial growth through enhanced manufacturing capabilities. Saurabh Agarwal, director at HAB Pharma, stated that the consolidation and new plants will provide capacity to meet rising demand for complex and high-quality pharmaceutical products. Urvee Garg, director at HAB Pharma, emphasised the company's focus on creating a more cohesive organisation serving both domestic and international markets. As part of its international expansion roadmap, the company is currently seeking European Union Good Manufacturing Practice (EU GMP) certification for further global expansion.
